-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Opus Genetics, Raises Price Target to $14

Benzinga·11/11/2026 11:38:26
Listen to the news
HC Wainwright & Co. analyst Matthew Caufield maintains Opus Genetics (NASDAQ:IRD) with a Buy and raises the price target from $8 to $14.